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Abstract.  The VLA-4 (CD49d/CD29) integrin  is the 
only member of the VLA family expressed by resting 
lymphoid cells that has been involved in cell-cell 
adhesive interactions.  We here describe the triggering 
of homotypic cell aggregation of peripheral  blood T 
lymphocytes and myelomonocytic cells by mAbs 
specific for certain epitopes of the human VLAo~4 
subunit.  This anti-VLA-4-induced cell adhesion  is iso- 
type and  Fc independent.  Similar to phorbol es- 
ter-induced homotypic adhesion,  cell aggregation  trig- 
gered through  VLA-4 requires the presence of divalent 
cations,  integrity of cytoskeleton and active metabo- 
lism.  However, both adhesion phenomena differed at 
their kinetics and temperature requirements.  Moreover, 
cell adhesion triggered through  VLA-4 cannot be in- 
hibited by cell preincubation  with anti-LFA-lc¢ 
(CDIla),  LFA-I~ (CD18), or ICAM-1  (CD54) mAb as 
opposed to that mediated by phorbol esters, indicating 
that it is a LFA-1/ICAM-1  independent process. Anti- 
bodies specific for CD2 or LFA-3  (CD58) did not 
affect the VLA-4-mediated cell adhesion.  The ability 
to inhibit this aggregation by other anti-VLA-4-specific 
antibodies recognizing epitopes on either the VLAa4 
(CD49d) or/3 (CD29) chains  suggests that VLA-4 is 
directly involved in the adhesion process. Further- 
more,  the simultaneous binding of a pair of aggre- 
gation-inducing  mAbs specific for distinct antigenic 
sites on the 0~4 chain resulted in the abrogation of cell 
aggregation.  These results indicate that VLA-4- 
mediated aggregation may constitute a novel leukocyte 
adhesion pathway. 
T 
HE integrin  superfamily  includes  receptors for extra- 
cellular matrix  (ECM) ~  components as well as recep- 
tors  involved  in  cell-cell adhesive  interactions  (19, 
38).  Structurally,  the integrin molecules are ot,:~ heterodi- 
mers,  in  which the c~ subunit is noncovalently  associated 
with the/3 chain.  Three subfamilies of integrins  have been 
classically described, each one defined by a common/3 sub- 
unit  (designated  as/31, ~2, and/33) that  shares  multiple  c~ 
subunits  (19, 38). 
The/32 integrins make up the leukocyte LFA-1, Mac-l, and 
p150,95 family (23, 34). Mac-1 and p150,95 function as com- 
plement receptors and they are also involved in the adhesion 
of monocytes and granulocytes to endothelial cells and other 
substrates.  The LFA-I member is implicated  in cell-cell in- 
teractions,  thus being  essential  in the adhesive  function  of 
all leukocyte cell types (23, 39). The/33 integrins are ECM 
protein receptors and  include  the vitronectin  receptor and 
platelet  glycoprotein  IIb/IIIa (20, 29). 
Finally, the/31 integrin subfamily, also known as VLA pro- 
teins, contains at least six different a chains (VLA-1-VLA-6). 
Among the VLA proteins, VLA-2, VLA-5, and VLA-6 func- 
I. Abbreviations  used in this paper:  ECM,  extracellular matrix; ICAM-I, 
intracellular  adhesion  molecule-l;  LFA, lymphocyte function-associated 
antigen; VLA, very late activation antigen. 
tion  as  receptors  for  ECM  proteins  such  as  collagen, 
fibronectin, and laminin,  respectively, whereas VLA-3 binds 
both fibronectin  and laminin  (5,  12,  13, 32, 38).  Recently, 
a role has been suggested for the VLA-4 integrin in intercel- 
lular  leukocyte interactions  (16, 40). Alternatively,  VLA-4 
can also function as a receptor for ECM components and has 
recently been shown to mediate T lymphocyte attachment  to 
human  fibronectin  (43). 
The VLA-4 integrin  is expressed  on thymocytes,  resting 
and activated peripheral  blood lymphocytes, monocytes, T 
and B cell  lines and myelomonocytic cell lines  (9,  13,  15, 
35). The association between c~4 and B chains is weaker than 
other VLA c~/~ heterodimers and it can be readily  broken 
by detergents or high ionic concentrations  (15, 35). Recently, 
cDNA clones for the a4 subunit have been isolated and se- 
quenced (40). 
Within the VLA family, VLA-4 is atypical because it is the 
only VLA heterodimer reported to participate in cell-cell in- 
teractions.  Thus, VLA-4 has been previously shown to be in- 
volved in effector-target cell association during cytolytic T 
lymphocyte-mediated  killing based on the inhibitory  effect 
exerted  by anti-VLA-4 mAb on this activity (7, 40).  Simi- 
larly, an anti-VLA-4 antibody was also suggested  to block 
heterotypic interaction  between helper and suppressor cells 
(21).  The  mouse  homologue  of  VLA-4,  designated  as 
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ing receptor (17). Moreover, the LPAM-1 ct chain can be 
found as two heterodimeric forms, one in association with 
/31 (LPAM-1), and another associated with a novel/3 chain 
(/3p)  (LPAM-2)  (18). Both  VLA-4  molecular  complexes 
function as accessory molecules in organ-specific adhesion 
to Peyer's patch high endothelial venules (HEV) (16). LFA-1, 
a member of the/32 family of integrin, is also involved in 
both leukocyte intercellular adhesive interactions and lym- 
phocyte binding to endothelium. Recently, an mAb specific 
for the LFA-1 ct subunit has been shown to trigger homotypic 
adhesion (22). 
To examine the possible role of VLA-4 in homotypic leu- 
kocyte interactions, we have assayed a wide panel of anti- 
VLA-4 mAb for both induction and inhibition of homotypic 
cell aggregation. The anti-VLA-4 HP antibodies used in this 
study were originally reported to recognize distinct epitopes 
of a novel association within VLA (35), now designated as 
VLA-4 (12,  15). Further detailed comparative biochemical 
and cell distribution studies of HP mAb with respect to other 
anti-VLA-4 reagents of the IV Leukocyte Differentiation An- 
tigen Workshop have demonstrated their specificity for the 
VLA-4 (CD49d) integrin (24,  36). 
The  present  report  demonstrates  that  homotypic  cell 
aggregation can be triggered by mAb specific for two differ- 
ent epitopes on VLAc¢4 chain. The study of the characteris- 
tics of this cell aggregation suggests that VLA-4 may consti- 
tute a cell adhesion pathway independent from that mediated 
through LFA-1/ICAM-1 molecules. 
Materials and Methods 
Cells 
Peripheral blood lymphocytes (PBL) were obtained from the heparinized 
venous blood of normal volunteers by  FicolI-Hypaque (Pharmacia Fine 
Chemicals, Uppsala, Sweden) centrifugation. T  cells were purified from 
peripheral blood mononuclear cells by removal of adherent cells on plastic 
petri dishes followed by passage through a nylon wool column. U-937 my- 
elomonocytic cell line and Jurkat and JM leukemic T cell lines were grown 
in RPMI 1640 medium (Flow Laboratories, Irvine, Scotland) supplemented 
with 10% FCS (Flow Laboratories), 2 mM L-glutamine, and 50 tzg/ml gen- 
tamicine (complete medium). 
Monoclonal Antibodies, F(ab')2 and Fab Fragments 
mAb HP1/I, HP1/3, HP1/7, HPI/2, HP2/1, HP2/4, HP2/7, and B-5GI0, are 
all directed against the c~ chain of VLA-4 (CD49d) (15, 35). mAb TS2/16 
and K20 recognize the/3 chain of VLA (CD29) (3, 14). mAb B-5GI0 and K20 
were obtained from the VLA panel of the IV Leukocyte Differentiation An- 
tigen Workshop. mAb TSI/I 1 and TS1/18 are specific for the c~ (CDI la) and 
/3  (CD18)  chains of LFA-1,  respectively  (34).  mAb  RR1/1  recognizing 
ICAM-I (CD54) (31) was kindly provided by Dr. T. A. Springer (Harvard 
Medical School, Boston, MA). mAb TS2/18 and TS2/9 recognize CD2 and 
LFA-3  (CD58), respectively (33). mAb W6/32 is specific for a monomor- 
phic determinant on HLA-A,B molecules (4). F(ab')2 and Fab fragments of 
anti-VLAc~4  HP2/4 mAb were prepared as previously described (28). 
Aggregation Assays 
Cells were washed twice with RPMI  1640 medium and resuspended to a 
concentration of 1  x  106 cells/ml for cell lines or 2  x  106 cells/ml for T 
lymphocytes. Aliquots of 50/~1 of cell suspensions  were added to each well 
of flat-bottomed,  96-well  microtiter  plates  (Costar  Corp.,  Cambridge, 
MA). Then 10 ~tl of appropriate mAb culture supernatants, purified mAb 
or its corresponding F(ab')2 and Fab fragments, or phorbol myristate ace- 
tate (Sigma Chemical Co., U.K.) were added to give a final concentration 
as indicated under each Figure.  Finally,  wells were filled with complete 
medium to a final volume of 100 p.I. Cells were allowed to settle into a cell 
incubator at 37"C and 5%  CO2 atmosphere. Then, cell aggregate forma- 
tion was determined at different periods of time by at least two independent 
observers by direct visualization of the plate with an inverted microscope. 
Photomicrographs were taken at varying times with a photo camera coupled 
to the microscope. We considered that aggregation induction assay was 
positive when more than 50% of the ceils were aggregated. 
For quantitative measurement of cell aggregation, a modification of the 
method described by Keizer et al. (21) was used. Cells were seeded in flat- 
bottomed microtiter plates as described above. The number of free cells was 
counted by using a special mask, consisting of squares (0.5 ram), under the 
plate. Within each well, at least five randomly chosen areas were counted, 
after which the mean and the total number of free cells by well was calcu- 
lated. Percent aggregation was determined by the following equation: per- 
cent aggregation  =  100  x  (l-[number of free cells])/(total  number of 
cells). The experiments were carried out in duplicate and the SD within 
each experiment was always <10%. 
Table L Effect on Leukocyte Homotypic Aggregation of  Different Anti-VLAoe4 (CD49d) and VLA-I~ (CD29) mAb 
Inhibition of PMA-induced  Induction of  VLA-4 
mAb  CD  Isotype  cell  aggregation*  cell  aggregation~  t  epitope§ 
HP 1  / 1  CD49d  IgG 1  -  + 
HPI/3  CD49d  IgG3  -  + 
HP I/7  CD49d  IgG 1  -  + 
HP2/7  CD49d  lgG2a  -  + 
HP 1/2  CD49d  IgG 1  -  - 
HP2/1  CD49d  IgG 1  -  - 
HP2/4  CD49d  IgGl  -  + 
B-5G 10  CD49d  IgG 1  -  - 
TS2/16  CD29  IgG 1  -  - 
K20  CD29  IgG2a  -  - 
TSI/18  CDI8  IgGl  +  - 
TSI/I 1  CD1 la  IgGl  +  - 
RR1  CD54  IgGl  +  - 
A 
A 
A 
A 
B 
B 
B 
* U-937 cells were preincubated for 30 min at 37°C with a  l:10 dilution of mAb culture supernatant before treatment with 20 ng/ml of PMA. 
~: U-937 cells were treated  with  I:10 dilution of mAb culture supernatant. 
§ VLAc¢4 epitopes are as previously described (16),  based on cross-blocking cell binding assays. 
Inhibition  or induction of cell  aggregation was estimated after 20 h of culture at 37°C as described in Materials and Methods. 
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Induction of cell aggregation 
Antibody 
mAb  CD  preparation  Peripheral blood T lymphocytes  U-937 cells 
HP2/4  CD49d  Total  Ig  +  + 
HP2/4  CIM9d  F(ab')_,  +  + 
HP2/4  CD49d  Fab  +  + 
HP2/1  CD49d  Total  Ig  -  - 
T lymphocytes and U-937 cells were treated either with 10 #g/ml of HP2/I purified lg, or with  I #g/ml of purified Ig, F(ab'h, or Fab fragments of HP2/4 mAb. 
Induction of cell aggregation  was estimated after 4 h of culture at 37°C as described  in Materials and Methods. 
Results 
Cell Adhesion Induced through Epitopes of 
VLA-4 Integrin 
To evaluate the possible role of  VLA-4 integrin in homotypic 
cell adhesion, we tested the functional effects of mAb against 
VLA-4 either on the induction or blockade of cell aggrega- 
tion, using the U-937 myelomonocytic cell line as a model. 
The results of this assay are summarized in Table I.  Four 
anti-a4 (CD49d) (HP1/1, HP1/3,  HP1/7 and HP2/7) mAbs, 
recognizing an identical or closely related antigenic site (epi- 
tope A), previously defined by cross-blocking binding ex- 
periments (35), were able to induce U-937 homotypic cell 
aggregation. The same result was obtained with one anti-or4 
(HP2/4) mAb specific for other different antigenic sites (epi- 
tope B). By contrast, no inductive effect on adhesion was ob- 
served with two anti-a4 (HPI/2 and HP2/I) mAb specific for 
site B, another anti-a4 (B-5G10) mAb, and two anti-B chain 
(CD29) mAb (Table I). Homotypic cell adhesion triggered 
through the VLA-4 integrin was also operative in resting pe- 
ripheral blood lymphocytes and purified T cells, as well as 
on leukemic T cell lines Jurkat and JM (Tables II and III and 
data not shown). 
Purified anti-VLA-4  HP2/4  mAb  as  well  as  the  corre- 
sponding F(ab')2  and Fab fragments triggered strong homo- 
typic cell adhesion (Table II). The effect was dose-dependent 
and could be observed at IgG and F(ab')2  fragment concen- 
trations as low as 50 ng/ml. However, higher concentrations 
of monovalent antibody  Fab  fragments  (0.5  #g/ml)  were 
Figure L Homotypic adhesion induced by anti-VLA-4 mAb. U-937 ceils were incubated for 20 h at 37°C in the presence of: (A) 10 #g/ml 
of  the noninducer aggregation purified anti-VLAo~4  HP2/1 mAb; (B) anti-VLA  fl chain TS2/16 mAb; (C) 1 #g/ml of the aggregation inducer 
anti-VLAot4 HP2/4 mAb; (D) 1 #g/ml of the F(alY)z fragment of HP2/4 mAb. Photomicrographs were taken after 20 h from the begin- 
ning of the assay. Bar, 250 #m. 
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Figure 2.  Kinetics of aggregation  of U-937 cells  induced  by anti- 
VLA-4 mAb. U-937 cells were incubated at 37°C either with 1 #g/ 
ml of HP2/4 mAb (o) or with 20 ng/ml of PMA (A). Aggregation 
was  quantitatively  determined  as  described  in  Materials  and 
Methods. 
necessary  to  induce cell  aggregation (data not shown).  A 
representative experiment that demonstrates the specificity 
of the  VLA-4-mediated  cell  adhesion  by  HP2/4  mAb  is 
visualized in Fig.  1 (C and D). The lack of induction of cell 
aggregation in the presence of either anti-VLA-4 HP2/1  or 
anti-VLA-/3 TS2/16  mAb is  also  shown  (Fig.  1,  A  and  B, 
respectively). 
Thus, the effect on cell aggregation of anti-VLA-4 mAb is 
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Figure 4. Cell aggregation through VLA-4 requires the presence of 
divalent cations. U-937 cells were preincubated  with 0, 1, or 10 mM 
EDTA for 30 min and then, either 1 #g/ml of HP2/4 mAb (shaded 
bars) or 20 ng/ml of PMA (open bars) were added for the following 
20 h of culture.  Then, percent of aggregation  was determined. 
isotype and Fc independent as well as epitope specific, since 
it is selectively induced by mAb to specific antigenic sites. 
Moreover, the cell aggregation assay has allowed the distinc- 
tion of two sites  with  different  functional behavior within 
epitope B, previously defined by cross-blocking binding ex- 
periments  (35). 
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Figure 3.  Temperature  dependence of the  VLA-4-mediated cell 
aggregation.  U-937 ceils  were incubated  at 37, 20, or 4°C either 
with  1 #g/ml of HP2/4 mAb (shaded bars) or with 20 ng/ml  of 
PMA (open bars). Percent of cell-cell homotypic adhesion  was 
measured  after  20  h  of culture  as  described  in  Materials  and 
Methods. 
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Figure 5, VLA-4 induced cell aggregation requires cytoskeleton in- 
tegrity  and active metabolism. U-937 cells were pretreated  for 30 
min at  37°C with  the  following  reagents:  no treatment;  20 /zM 
cytochalasin B; or a mixture of 50 mM 2-deoxy-D-glucose plus  10 
mM sodium azide.  Then, cells  were treated  either with  1 /zg/ml 
HP2/4 mAb (shaded bars) or with 20 ng/ml PMA (open bars) for 
the following 20 h of culture,  and the aggregation  was quantified. 
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Next, we studied the characteristics of VLA-4-mediated cell 
adhesion compared with that induced by phorbol esters. The 
kinetics of the homotypic adhesion were clearly different in 
both systems (Fig.  2).  Cell adhesion could be rapidly in- 
duced in the presence of anti-VLA-4 mAb and was observed 
after  1 h  of mAb treatment,  reaching the plateau at 8 h, 
when the PMA-induced aggregation had not yet taken place. 
Therefore, both stimuli appear to be using different pathways 
for triggering cell aggregation. 
Differences between both adhesion systems were also ob- 
served by studying the temperature requirements (Fig. 3). 
Although no aggregation was found with both stimuli at 4°C, 
the anti-VLA-4  mAb was  able to exert its effect at 20°C, 
whereas no cell aggregation was observed with PMA under 
these conditions. Both anti-VLA-4  and PMA induced cell 
adhesion at 37°C. 
Similarly to cell adhesion triggered by PMA, VLA-4-me- 
diated cell aggregation required the presence of divalent cat- 
ions as demonstrated by the dose-dependent inhibitory effect 
of the Ca2÷/Mg  2÷ chelating agent EDTA (Fig. 4). Moreover, 
the integrity of cytoskeleton as well as an active metabolism 
were also necessary in both anti-VLA-4  and PMA induced 
cell adhesions since inhibitors of  both processes totally abro- 
gated the adhesion inductive effects (Fig. 5). 
VLA-4-induced Cell Aggregation Is Independent of 
LFA-1/ICAM-I Adhesion Pathway 
Homotypic adhesion can also be induced by mAb against 
such molecules as syalophorin (26). In this case, the aggrega- 
tion appears  to be LFA-1/ICAM-1 mediated.  To ascertain 
whether VLA-4-mediated cell aggregation was functionally 
related to the LFA-1/ICAM-1 molecular adhesion pathway, 
cross-blocking cell adhesion experiments were carried out 
by using as inhibitors mAb specific for the LFA-1 complex 
(CDlla, CD18)  and the ICAM-1  (CD54) molecule. 
U-937 cells or peripheral blood T lymphocytes were pre- 
incubated with anti-CD18 mAb, and then, either PMA or the 
adhesion inducer anti-a4 HP1/7 mAb were added as induc- 
tive stimuli.  The anti-CD18  mAb  virtually abolished the 
PMA-induced adhesion, but did not affect the VLA-4 medi- 
ated cell aggregation (Table III and Fig. 6, A and B, respec- 
tively). The same results were obtained by using as inhibi- 
tors mAb specific for CD1 la and ICAM-1 molecules (Tables 
I and III). Furthermore, when anti-LFA-1 mAb were added 
after disruption of VLA-4-induced cell aggregates no inhibi- 
tory effects were observed (data not shown). These results 
indicate that VLA-4-mediated cell adhesion is functionally 
independent of LFA-1/ICAM-1 adhesion pathway. 
Similar studies of cross-blocking cell adhesion performed 
on purified T cells with anti-VLA-4 as adhesion inducer mAb 
and anti-LFA-3 (CD58) and anti-CD2 as inhibitor mAb also 
indicated that both VLA-4 and CD2/LFA-3 adhesion mecha- 
nisms are functionally  unrelated and independent (Table III). 
Blockade of Cell Aggregation by Simultaneous Binding 
of  Antibodies Specific for Different Sites on VLAcd 
and 13 Chains 
To determine whether the VLA--4 molecule itself was medi- 
ating the U-937 homotypic adhesion triggered by anti-VLAo~4 
mAb, we analyzed the influence on cell aggregation of the 
simultaneous binding of pairs of different mAbs specific for 
different antigenic sites on a4 and/3 VLA chains. Preincuba- 
tion of U-937  cells with anti-VLA ~  or  the  anti-VLAa4 
HP2/1, a non-adhesion-inducing mAb specific for epitope B, 
resulted in a profound inhibitory effect of VLA-4 mediated 
adhesion through ct4  epitope A  (Fig.  6,  E  and F,  respec- 
tively). By contrast, none of them affected PMA-mediated 
adhesion (Fig. 6, B and C and Table I). 
The functional interferences in cell aggregation of mAb- 
binding to distinct epitopes localized in both a4 and/~ chains 
of the VLA-4 complex are summarized in Table IV. All anti- 
bodies  specific  for  a4  site  B,  including  the  adhesion- 
inducing (HP2/4) and noninducing (HP2/1 and HP1/2) mAb, 
were able to virtually abrogate cell aggregation triggered by 
mAb directed to or4 site A (HP1/1 and HP1/7). Similar inhibi- 
tory effects were observed in reciprocal experiments using 
as adhesion-inducer the mAb specific for site B  (HP2/4). 
Moreover,  the  non-adhesion-inducing anti-VLAot4  HP2/1 
mAb was able to disperse cell aggregates preformed by treat- 
ment with adhesion inducers anti-VLAct4  mAb  (data not 
shown).  On the other hand, the anti-VLA/3 TS2/16  mAb 
blocked cell aggregation induced by anti-VLA-4  mAb spe- 
cific either for site A or site B. No inhibition of aggregation 
Table 1II. VLA-4-mediated  Homotypic Cell Adhesion Is LFA-1/ICAM-1 and CD2/LFA-3  Independent 
Cell aggregation induced by anti-VLA-4 
mAb inhibitor  Specificity  (CD)  Peripheral  blood T  lymphocytes  U-937 cells 
None  67  96 
TSI/11  LFA-Io~ (CDI la)  62  96 
TSI/18  LFA-/3 (CDi8)  64  93 
RR1/1  ICAM-1  (CD54)  70  85 
TS2/18  LFA-2 (CD2)  69  95 
TS2/9  LFA-3  (CD58)  73  98 
TS2/16  VLA-/3 (CD29)  28  37 
HP2/I  VLA-ot4 (CD49d)  10  20 
W6/32  HLA-A,B  55  100 
T lymphocytes and U-937 cells were preincubated for 30 min at 37°C with 10 p,I of inhibitor culture supernatant mAb before treatment with I ttg/ml of adhesion 
inducer anti-VLA-4 HPI/7 mAb. Percentages of aggregation were calculated  after 20 h of culture as described in Materials and Methods. Similar results were 
obtained when cell aggregation was monitored at 4 h. 
Campanero et al.  VLA-4 Leukocyte Adhesion Pathway  2161 Figure 6. Cell aggregation induced by ami-VLA-4 mAb is LFA-I/ICAM-I independent, but is interfered by other anti-VLA-4 mAb. U-937 
cells were pretreated for 30 min at 37°C with 10 #l of culture supernatant containing the following mAbs: anti-LFA-/~ TS1/18  (A and D); 
anti-VLA-B TS2/16 (B and E); anti-VLA-4 HP2/I  (C and F).  Then, cells were treated either with 20 ng/ml PMA (A-C) or with l  ttg/ml 
HPI/7 mAb (D-F) and photomicrographs were taken after 20 h of culture. It is important to note that HPI/7 mAb recognizes an antigenic 
site (epitope A) on VLAct4 topographically unrelated to the one defined by HP2/1  mAb (epitope B).  Bar, 250/~m. 
Table IV. Cross-Neutralizing  Effect of  Leukocyte Adhesions by Simultaneous Binding of  Anti-VLA-4 mAbs Specific 
for Distinct Epitopes 
lnhibitors (mAbs) 
Adhesion inducing  W6/32  TSI/18  HPI/I  HPI/7  HP2/I  HP2/4  TS2/16 
mAb  (HLA-A,B)  (CDI8)  (CD49d A)  (CD49d A)  (CD49d B)  (CD49d B)  (CD29) 
Cell aggregation (%) 
HP1/1  (CD49d A)  82  80  79  85  11  9  28 
HPI/7  (CD49d A)  85  82  75  87  10  12  25 
HP2/4 (CD49d B)  73  75  17  15  9  70  22 
U-937 cells were preincubated for 30 min at 37°C with 10 ~tl of inhibitor culture supernatant mAb before treatment for the next 20 h at 37°C with I /zg/ml of 
the adhesion-ioducing mAb. Afterwards, the percentage of cell aggregation was quantitatively estimated as described in Materials and Methods. Similar results 
were obtained when cell aggregation was monitored at 4 h. 
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CD18 mAb. 
The inhibitory effects of anti-VLA-4 mAb indicate that 
VLA-4 may be directly involved in the adhesion mechanism, 
although signaling through VLA-4 cannot be ruled out. In 
addition, these results demonstrate the existence of at least 
two different sites on the or4 chain involved in the induction 
of homotypic cell adhesion.  Moreover, cell adhesion trig- 
gered by mAb binding to one site can be affected by mAb 
binding to another site on the same chain or on the associated 
chain. 
Discussion 
In this study, we report data indicating that VLA-4 integrin 
can mediate leukocyte cell homotypic adhesions. We have 
found that antibodies recognizing at least two topographi- 
cally distinct epitopes on the VLAc~4 chain are capable of 
specifically inducing leukocyte cell clustering formation, and 
that this cell aggregation can be inhibited by other anti-VLA- 
4  mAb. 
Our results indicate that leukocyte cell adhesion triggered 
through VLA-4 is a process that is Fc independent and site 
specific, because anti-VLAc~4 antibodies of identical isotype 
but directed to other distinct epitopes on the same c~4 chain 
did  not  induce  cell  aggregation.  Moreover,  anti-VLAo~4 
F(ab')2 and Fab fragments were able to trigger cell-ceU ad- 
hesion.  However, since higher concentrations of Fab frag- 
ments were necessary to trigger the cell aggregation, the pos- 
sibility  cannot  be  ruled  out  that  cross-linking  of VLA-4 
molecules on individual cells could also contribute in part 
to the homotypic adhesion phenomena. Similar results have 
been recently described for LFA-1, another receptor molecule 
of the integrin family involved in leukocyte cell-cell adhe- 
sive interactions. An antibody to a novel and unique activa- 
tion epitope on LFA-I ot chain was able to induce homotypic 
cell adhesion, which could be blocked by other anti-LFA-1 
mAb  specific  for other  distinct  epitopes  (22).  Similarly, 
simultaneous binding of anti-VLA-4 antibodies specific for 
distinct epitopes localized either on the or4 or on the B chains 
resulted in the abrogation of VLA-4-mediated cell clustering 
formation. Hence, VLA-4-mediated cell adhesion, as well as 
that described for LFA-I,  appears to be epitope dependent. 
In a previous study, we identified two distinct antigenic sites 
(A and B) on the VLAot4 chain defined by cross-blocking 
cell binding assays (35). The cell aggregation assay has now 
allowed the further definition of two sites displaying different 
functional behavior within epitope B. The relation between 
these antigen epitopes and putative functional domains awaits 
further studies. 
Comparison of requirements of VLA-4-mediated adhesion 
with  cell clustering  formation induced  by phorbol  esters 
(LFA-1 mediated) (30) reflects similarities and differences. 
Both adhesion phenomena require divalent cations, integrity 
of the cytoskeleton, and active metabolism.  However, cell 
aggregation triggered by anti-VLA-4 mAb takes place more 
rapidly than that induced by PMA. Most importantly, phor- 
bol  ester-induced  adhesion is  LFA-1/ICAM-1  dependent, 
whereas VLA-4 mediated seems to be functionally indepen- 
dent because antibodies specific for both LFA-1 and ICAM-I 
molecules did not interfere with the anti-VLA-4 triggering of 
cell aggregation. Likewise, the VLA-4 adhesion pathway is 
also functionally independent of the CD2/LFA-3 adhesion 
mechanism (37). 
There are  two possible  alternative explanations  for the 
adhesive effect induced by anti-VLA-4 mAb. First, confor- 
mational changes on the VLA-4 integrin mediated by anti-or4 
mAb binding may result in a functionally active form of the 
molecule enabling the interaction with a ligand(s) present ei- 
ther on the cell membrane or in the extracellular environ- 
ment.  In  this  sense,  conformational changes  taking place 
during cell activation have been detected in gplIb/IIIa, Mac-l, 
and LFA-1 integrins resulting in active forms with higher 
efficiencies in their respective receptor-ligand interactions 
(1, 2,  8,  10, 20,  29, 44). 
Second, triggering of intracellular signals by anti-integrin 
antibodies could also play a role in cell adhesion cluster for- 
mation  (10).  Hence,  anti-LFA-1  mAb have been  reported 
both to influence intracellular Ca  2÷ levels and to induce T 
cell mitogenesis in conjunction with submitogenic concen- 
trations of anti-CD3 mAb (6, 41, 42). Recently, the induction 
of CIM+ T cell proliferation which is inhibitable by an anti- 
VLA-/3 (CD29) antibody has been observed by interaction 
of fibronectin  with  the  VLA-5  receptor  in  a  serum-free 
medium culture system (25).  Similar inhibitory effects by 
anti-CD29 mAb have been recently reported in CD4 +  T cell 
proliferation triggered by CD2 or CD3 (21). These authors 
also detected an increase in cyclic AMP levels induced on 
activated T cells by anti-CD29 antibody, probably playing a 
role in these negative signaling effects (21). It will be of in- 
terest to measure cAMP concentration in cells treated with 
either inducer or noninducer adhesion anti-VLA-4 antibod- 
ies  to learn  whether a  relation between  induction of cell 
adhesion and levels of this second messenger could be estab- 
lished. 
Recently, a  function has been ascribed to VLA-4 as an 
ECM protein receptor, similarly to that described for other 
VLA members (12,  13).  The attachment of T lymphocytes 
to a 38-kD fragment, containing the Hep II domain and the 
type III connecting segment of  human plasma fibronectin has 
been demonstrated to be mediated through the VLA-4 inte- 
grin (43). In addition, VLA-4 has also been found to interact 
with a novel cytokine-inducible adhesion molecule on en- 
dothelial cells, designated as VCAM-1 (11). This endothelial 
molecule functions as an adhesion ligand that binds lympho- 
cytes and, like ICAM-1 and ICAM-2, the two ligands of LFA-1 
(37), is a member of the immunoglobulin gene superfamily 
(27).  Thus,  VLA-4 constitutes a  singular example of a ~1 
integrin having a role in both celI-ECM and cell-cell ad- 
hesion functions through  two identified ligands,  fibronec- 
tin and VCAM-1.  Furthermore, the sites of interaction of 
VLA-4 with either VCAM-1 on endothelial cells or fibronec- 
tin mapped on distinct domains of ct4 by means of two anti- 
bodies here studied  (HP1/3  and HP2/1),  representing epi- 
topes A and B, respectively. 
Therefore, it will be of interest to study the possible rela- 
tionship of  the inductive effect  on cell aggregation of  different 
mAbs directed to VLAa4 with their effects on these two 
novel receptor functions described for VLA-4 (11, 43). Lym- 
phocyte binding to either fibronectin or endothelial cells pro- 
vides good models to test whether VLA-4 function could be 
modulated by mAb binding to different antigenic sites. 
The biological  significance of the  homotypic adhesion 
triggered by anti-VLA-4 mAb remains unknown. It is con- 
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resembles  the effect  of the interaction of VLA-4  receptor 
with one or more physiological ligands.  In this sense,  we 
have observed that homotypic cell adhesion triggered through 
VLA-4 requires the presence of certain amounts of serum 
(Campanero,  M.  R.,  et  al.,  unpublished  observations). 
Whether fibronectin or other cell interacting serum proteins 
are components necessary for the induction of cell adhesion 
needs to be elucidated. 
On the other hand, we have found that cell adhesion trig- 
gered by mAb binding to one epitope on ~4 can be blocked 
by mAb binding to another epitope on the same chain or on 
the associated ~  chain. These results may indicate that cell 
adhesion triggered through VLA-4, similar to that which is 
LFA-I/ICAM-1  mediated (10), is a dynamic and reversible 
process, where adhesion-deadhesion could be regulated by 
binding of either specific  antibodies or multiple ligands to 
different sites of the receptor molecule. Thus, our finding of 
at least two sites on the a4 chain involved in triggering of 
cell adhesion, which are topographically separated but func- 
tionally interdependent, may provide a suitable, simple, and 
rapid system to test the influence of multiple ligand interac- 
tions. 
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